<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

Long-term safety of epicutaneous immunotherapy with DBV712 for peanut allergy

by Contemporary Pediatrics | February 27, 2024
placeholder

"The biggest takeaway from the long-term study of Viaskin for the treatment of peanut allergy is the continued data that show the high safety profile of the treatment, making it an attractive future treatment option for patients, families, and clinicians," David M. Fleischer, MD, director, Allergy and Immunology Center, Children's Hospital Colorado, and study author told Contemporary Pediatrics.

Topics: Press Coverage